Paliperidone | Essential medicine status ✔
---|---
**Section:** 24. Medicines for mental and behavioural disorders ➔ 24.1. Medicines for psychotic disorders

### Indication
- Schizophrenia or other primary psychotic disorders

### INN
- Paliperidone

### Medicine type
- Chemical agent

### List type
- Core

### Formulations
- Parenteral > General injections > IM:
  - 25 mg in pre-filled syringe (as palmitate)
  - 50 mg in pre-filled syringe (as palmitate)
  - 75 mg in pre-filled syringe (as palmitate)
  - 100 mg in pre-filled syringe (as palmitate)
  - 150 mg in pre-filled syringe (as palmitate)

### EML status history
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

### Sex
- All

### Age
- Adolescents and adults

### Therapeutic alternatives
- Risperidone (ATC codes: N05AX08)

### Patent information
- Patents have expired in most jurisdictions
- Read more about patents.

### Summary of evidence and Expert Committee recommendations
The Expert Committee did not recommend inclusion of paliperidone palmitate 3-month long-acting injection on the EML for maintenance treatment of schizophrenia. The Committee noted that compared to the 1-month formulation, the 3-month formulation has evidence of similar clinical efficacy and safety and may offer advantages to patients in terms of fewer injections. However, the Committee noted that it is not recommended to initiate treatment with the 3-month formulation, rather it is used in patients who demonstrate benefit and tolerance to the 1-month formulation over at least 4 months. In addition, the 3-month formulation is more highly priced, not yet available as generic, and currently has limited availability in low- and middle-income countries.